{
    "clinical_study": {
        "@rank": "104104", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg."
            }, 
            {
                "arm_group_label": "Saxagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Saxagliptin 5mg tablet by mouth every day for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune\n      cells in healthy subjects and patients with type 1 diabetes"
        }, 
        "brief_title": "Incretin Effect on the Immunological Phenotype", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "Assessment of immunological effects of Saxagliptin and Liraglutide on immune cells of the\n      peripheral blood."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -healthy subjects or patients with type 1 diabetes\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  treatment with GLP-1-Analoga (Liraglutide, Exenatide)\n\n          -  treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin)\n\n          -  chronic disease including a long-term medication over 4 weeks per year (except type 1\n             diabetes)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782261", 
            "org_study_id": "ADPP004", 
            "secondary_id": "2011-006300-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "description": "once daily subcutaneous injection", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }, 
            {
                "arm_group_label": "Saxagliptin", 
                "description": "once daily tablet", 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Onglyza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Incretins", 
                "Saxagliptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "autoimmune disease", 
            "diabetes type 1", 
            "incretin effect"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University Graz"
            }, 
            "investigator": [
                {
                    "last_name": "Thomas Pieber, Prof.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Gerlies Treiber, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects", 
        "overall_contact": {
            "email": "gerlies.treiber@medunigraz.at", 
            "last_name": "Gerlies Treiber, MD", 
            "phone": "+43/316/38512383"
        }, 
        "overall_contact_backup": {
            "email": "silvia.leitgeb@medunigraz.at", 
            "last_name": "Silvia Leitgeb, Bcs", 
            "phone": "+43/316/38512383"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Graz", 
            "last_name": "Thomas R Pieber, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the effects of incretin based therapy on regulatory FOXP3+ T cells will be measured at baseline and after 4 weeks", 
            "measure": "Increase of regulatory FOXP3+ T cells", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The effect of incretin based therapy on circulating immune cells and cytokine secretion at baseline and after 4 weeks", 
            "measure": "Immunophenotyping", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}